Clinical Trial Update: DBPC-Dose-finding-trial of Vitamin D3 for SCIT in Birch Pollen Allergic Patients. [Phase 2]

View source ↗

Summary

Phase 2 dose-finding trial of Vitamin D3 as an adjuvant for subcutaneous immunotherapy in birch pollen hypersensitivity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypersensitivity

Drugs mentioned

• SCIT
• Vitamin D3 (Cholecalciferol)

Snippet

Sponsor: Laurian Jongejan | Conditions: Hypersensitivity | Phase 2 | Status: COMPLETED